Find a study
Browse recruiting studies near you — free to check, always your choice.
62 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- DepressionAnxiety
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
Testing personalized brain stimulation for ongoing concussion symptoms
📍 UCLA · Westwood, Los Angeles, CA · Get directions →
The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.
- Multiple sclerosis (MS)
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Testing the safety and effects on disease and immune cells of one dose of YTB323 in people with
📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
- DepressionAnxiety
iTBS+D-Cycloserine for Youth Suicide
Testing a treatment for depression and anxiety to reduce youth suicide risk
📍 University of Calgary · Calgary, Alberta · Get directions →
Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives.
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- Anxiety
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Testing whether sertraline works better than a placebo for anxiety in children with
📍 Alberta Children's Hospital - University of Calgary · Calgary, Alberta · Get directions →
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs.
- DepressionAnxiety
Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City
Testing whether a phone-based program supports opioid recovery and mental health
📍 Washington University School of Medicine · St Louis, MO · Get directions →
The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis
📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Anxiety
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Testing whether adding ABBV-932 to antidepressants is safe and helps adults with generalized anxiety
📍 University of Alabama - Huntsville Regional Medical Campus /ID# 267818 · Huntsville, AL · +39 more US sites · Get directions →
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
- Multiple sclerosis (MS)
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple
📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
- Multiple sclerosis (MS)
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Testing whether corticosteroids change inflammation in acute MS lesions
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.
- Multiple sclerosis (MS)
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Testing solriamfetol to treat tiredness from multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · Get directions →
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.
- DepressionAnxiety
A New Intervention to Improve Function in Veterans With Anxiety and Depression
Testing a new treatment to improve daily functioning in veterans with anxiety and depression
📍 Durham VA Medical Center, Durham, NC · Durham, NC · Get directions →
Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain.
- Multiple sclerosis (MS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Testing whether TRX319 is safe for people with progressive multiple sclerosis
📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?
- DepressionAnxiety💵 May compensate
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer
📍 MD Anderson Cancer Center · Houston, TX · Get directions →
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
- DepressionAnxiety💵 May compensate
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors
📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →
This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.
- Anxiety
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Testing whether a single dose injection reduces anxiety symptoms
📍 Lighthouse Psychiatry · Gilbert, AZ · +21 more US sites · Get directions →
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
- Multiple sclerosis (MS)
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
- DepressionAnxiety
Psilocybin-Assisted Therapy for Intergenerational Trauma
Testing psilocybin-assisted therapy for depression and anxiety in children of genocide survivors
📍 The Parsons Research Center for Psychedelic Healing · New York, NY · Get directions →
This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.
- Multiple sclerosis (MS)
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Testing whether special MRI using hyperpolarized carbon can predict how relapsing-remitting MS
📍 Byers Hall · San Francisco, CA · Get directions →
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.
- DepressionAnxiety
Cannabis for Palliative Care in Cancer
Testing cannabis for symptom relief and side effects in cancer patients
📍 Anschutz Health Sciences Building · Aurora, CO · Get directions →
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required.
- DepressionAnxiety
Pramipexole to Enhance Social Connections
Testing whether pramipexole improves social connectedness in adults with anxiety or depression
📍 University of California, San Diego · San Diego, CA · +1 more US site · Get directions →
This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute).
- Anxiety
Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults
Testing a marijuana-based compound to treat anxiety in autistic adults
📍 Southwest Autism Research and Resource Center · Phoenix, AZ · Get directions →
The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC.
- DepressionAnxiety
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
Testing a cognitive training program to see brain and thinking changes in people with depression or
📍 UC San Diego · San Diego, CA · Get directions →
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.
- DepressionAnxiety
Modulating Exercise Dosage to Improve Concussion Recovery
Testing whether a higher amount of aerobic exercise helps concussion recovery
📍 University of Colorado Denver · Aurora, CO · +2 more US sites · Get directions →
Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 14 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae.
- DepressionAnxiety
Cannabidiol and Older Adult Cannabis Users
Testing how hemp CBD and THC affect mood and anxiety in older adults
📍 University of Colorado at Boulder · Boulder, CO · Get directions →
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo.
- DepressionAnxiety💵 May compensate
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
Testing whether pregnenolone pills affect brain function and depression in people with HIV
📍 Massachusetts General Hospital · Boston, MA · Get directions →
This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications.
- Multiple sclerosis (MS)
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Testing metformin alone or with other treatment in older people with multiple sclerosis
📍 UBMD Neurolgy · Buffalo, NY · Get directions →
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy.
- DepressionAnxiety
Family Acceptance Project Online (Pilot RCT)
Testing an online program to reduce depression and anxiety in LGBTQ youth by improving family
📍 University of Michigan · Ann Arbor, MI · Get directions →
Research shows that sexual and gender minority youth (SGMY) experience high rates of mental health problems and other challenges (e.g., social, academic). A major factor that leads to these challenges is family rejection (family behaviors and reactions that minimize, deny, ridicule and attempt to prevent or change a child's sexual orientation, gender identity and gender expression).
- Anxiety
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
Testing a music-based therapy added to CBT to treat anxiety in children
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Anxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression.
- DepressionAnxiety
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
Testing group retreat psilocybin therapy for anxiety and depression in people with advanced cancer
📍 Fred Hutch/University of Washington Cancer Consortium · Seattle, WA · Get directions →
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering.
- DepressionAnxiety
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
Testing brain stimulation targets to change behavior in depression or anxiety
📍 Acacia Clinics · Sunnyvale, CA · +1 more US site · Get directions →
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
- Multiple sclerosis (MS)
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Testing whether clemastine fumarate changes MRI signs of nerve repair in people with multiple
📍 Sandler Neurosciences Building, Neurological Clinical Research Unit · San Francisco, CA · Get directions →
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of multiple sclerosis.
- Multiple sclerosis (MS)
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Testing a nasal treatment in people with non-active secondary progressive multiple sclerosis
📍 Brigham and Women's Hospital · Boston, MA · Get directions →
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension study with an opportunity for dose to be escalated based on the subject's clinical status.
- Multiple sclerosis (MS)
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
Testing cognitive behavioral therapy to treat insomnia symptoms in people with multiple sclerosis
📍 University of Kansas Medical Center · Kansas City, KS · Get directions →
The incidence of insomnia is estimated to be as high as 90% in individuals with MS due to insomnia being underdiagnosed. Sleep disturbances in people with MS have been associated with reduced cognitive performance, physical function, psychological well-being, quality of life, and occupational function, as well as increased prevalence of fatigue, pain, depression, and anxiety.
- Multiple sclerosis (MS)
Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
Testing telehealth versus web-based CBT for sleep and fatigue in people with multiple sclerosis
📍 University of Kansas Medical Center- Sleep, Health and Wellness Laboratory · Kansas City, KS · Get directions →
The objective of this RCT is to assess the efficacy of one-on-one telehealth CBT-I (tCBT-I) compared to web-based CBT-I (wCBT-I) and treatment as usual (TAU) to improve sleep outcomes (Aim 1), fatigue and quality of life (Aim 2), and promote neuroprotection (Exploratory Aim 3), and to explore the characteristics of participants that predict improvement in sleep outcomes (Exploratory Aim 4). Reassessment of outcomes will be completed after the 6-week intervention and 6 months following completion of interventions.
- Multiple sclerosis (MS)
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Testing how fenebrutinib affects the body and safety in children with relapsing multiple sclerosis
📍 INECO Neurociencias Orono · Rosario, Santa Fe Province · Get directions →
This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period.
- High cholesterol
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults
📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).
- Anxiety
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Testing a second add-on medicine for generalized anxiety disorder
📍 Clinical Site · Chandler, AZ · +33 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
- Anxiety
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Testing whether a 3 mg psilocybin mouth solution is safe for anxiety
📍 Kingston General Health Research Institute · Kingston, Ontario · Get directions →
This Phase 2a clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of a 3 mg dose of psilocybin oral solution for the treatment of Generalized Anxiety Disorder (GAD). The study consists of three sequential phases: Screening Phase (up to 4 weeks), Open-label Run-in Phase (4 weeks), Double-blind Treatment Phase (4 weeks) Screening Phase During the Screening Visit, participants will provide informed consent and undergo a comprehensive medical evaluation, including an abbreviated psychiatric assessment, to determine eligibility.
- Anxiety
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Testing an anxiety medicine by itself for generalized anxiety disorder
📍 Clinical Site · Birmingham, AL · +29 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
- Multiple sclerosis (MS)
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Testing the safety of an mRNA treatment to help prevent multiple sclerosis relapses
📍 Boston Clinical Trials Inc - Internal Medicine · Boston, MA · +7 more US sites · Get directions →
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
- Multiple sclerosis (MS)
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
Testing whether starting metformin at different times is feasible in youth with multiple sclerosis
📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.
- Anxiety
Use of CBD in the Treatment of Anxiety
Testing hemp-based CBD doses for anxiety symptoms and sleep
📍 University of Florida · Gainesville, FL · Get directions →
This study will examine the doses, safety, and test the preliminary efficacy of hemp-derived CBD product for improving anxiety symptoms and sleep disturbances among individuals with anxiety. A 4-week, randomized, double-blind, placebo-controlled trial will be conducted to determine the safety, tolerability, preliminary efficacy, and acceptability of 50 to 150 mg/day of CBD.
- Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD
📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
- Anxiety
A Study of NTX-1472 in Social Anxiety Disorder
Testing whether NTX-1472 is safe for adults with social anxiety
📍 SOAR Clinical Study Site · Encino, CA · +10 more US sites · Get directions →
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD?
- DepressionAnxiety
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder
Testing magnesium plus vitamin B6 (with usual care) for depression and anxiety in people with
📍 McLean Hospital · Belmont, MA · Get directions →
This is a randomized, double-blind, placebo-controlled proof-of-concept clinical trial to assess the efficacy and safety of Magnesium-vitamin B6in combination with treatment as usual for treating symptoms of depression, stress, and anxiety in patients with first episode bipolar I disorder.
- DepressionAnxiety
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Studying brain and thinking patterns in children with anxiety disorders
📍 National Institutes of Health Clinical Center · Bethesda, MD · +1 more US site · Get directions →
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).
- Dementia / Alzheimer'sMultiple sclerosis (MS)
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Testing PET brain scans to measure immune cell activity in dementia
📍 Brigham MS Center, 60 Fenwood Road · Boston, MA · Get directions →
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
- Multiple sclerosis (MS)
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Testing how single or combined medicines affect MS biomarkers
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.
- High cholesterolLupus (SLE)
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Testing certolizumab added to usual treatment to improve pregnancy in lupus and antiphospholipid
📍 Hospital for Special Surgery · New York, NY · +1 more US site · Get directions →
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.
- Multiple sclerosis (MS)
Molecular Imaging of NET Using [C-11]MRB-PET in MS
Using PET scans to study brain norepinephrine transporter injury in MS
📍 Brigham MS Center, 60 Fenwood Road · Boston, MA · Get directions →
This study aims to use \[C-11\]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals. The overarching hypothesis is that there is decreased radioligand binding to the norepinephrine transporter in multiple sclerosis, reflecting injury to the noradrenergic system and that it plays a role in disease pathogenesis, its clinical manifestations and severity.
- DepressionAnxiety
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
Testing daily low-dose psilocybin to treat anxiety and depression in advanced illness patients
📍 The Ottawa Hospital · Ottawa, Ontario · Get directions →
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the safety, feasibility, therapeutic dose, and preliminary efficacy of psilocybin microdosing to treat psychological distress among patients with advanced illness. Forty patients will receive psilocybin drug product (1-3mg per day, Mon-Fri) for 4 weeks to be administered via oral capsules by the participant.
- Anxiety
Study of Dextromethorphan in OCD and Related Disorders
Testing dextromethorphan with fluoxetine for OCD symptoms and anxiety
📍 Stanford University · Stanford, CA · Get directions →
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
- Multiple sclerosis (MS)
Cannabis as a Complementary Treatment in Multiple Sclerosis
Testing cannabis as an add-on treatment for multiple sclerosis
📍 CRCHUM · Montreal, Quebec · Get directions →
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS symptoms is limited.
- DepressionAnxiety
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
Testing whether a brain drug affects decision-making in depression and anxiety
📍 Mclean Hospital · Belmont, MA · Get directions →
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
- Multiple sclerosis (MS)
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Testing how CBD, THC, or both affect sleep and pain in people with MS
📍 University of Michigan · Ann Arbor, MI · Get directions →
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
- DepressionAnxiety
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
Testing combined sleep treatments to improve sleep and mood in people with advanced cancer
📍 MD Anderson Cancer Center · Houston, TX · Get directions →
To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study.
- Anxiety
Evaluating Buspirone to Treat Opioid Withdrawal
Testing buspirone for anxiety and opioid withdrawal symptoms during tapering
📍 Kahlert Institute for Addictino Medicin · Baltimore, MD · Get directions →
The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting opioid, undergo an opioid stepwise taper, and complete a post-taper observation period where participants will have the opportunity to initiate long-term buprenorphine or extended-release naltrexone.
- Anxiety
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Testing a repeat nasal spray dose for quick relief of acute anxiety in adults with social anxiety
📍 Vistagen Clinical Site · Sherman Oaks, CA · +8 more US sites · Get directions →
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting.
- Showing the first 60 of 62. Add filters or a location to narrow down.